Efficacy of BMS-986016, a Monoclonal Antibody That Targets Lymphocyte Activation Gene-3 (LAG-3), in Combination With Nivolumab in Pts With Melanoma Who Progressed During Prior Anti–PD-1/PD-L1 Therapy in All-Comer & Biomarker-Enriched Populations

Date
March 30, 2018
Explore related products in the following collection:

 

Efficacy of BMS-986016, a Monoclonal Antibody That Targets Lymphocyte Activation Gene-3 (LAG-3), in Combination With Nivolumab in Pts With Melanoma Who Progressed During Prior Anti-PD-1/PD-L1 Therapy  in All-Comer & Biomarker-Enriched Populations
 
PA Ascierto1, P Bono2, S Bhatia3, I Melero4, M Nyakas5,  IM Svane6, J Larkin7, CA Gomez-Roca8, D Schadendorf9, R Dummer10, A Marabelle11, C Hoeller12, M Maurer13, C Harbison13, P Mitra13, S Suryawanshi13, K Thudium13, E Muñoz-Couselo14, S Harnois1
1IRCCS Pascale, , Italy; 2HUS, Finland; 3UW SCCA, Usa; 4CUN; 5OUS, Norway; 6KU Herlev Hospital, Denmark; 7Royal Marsden Hospital, Uk; 8IUCT, France; 9WTZ Essen, Germany; 10UZH, Switzerland; 11Gustave Roussy, France; 12Medical University of Vienna, Austria; 13BMS,  Usa; 14Vall d´Hebron Institute of Oncology, Spain
 
Background: Simultaneous blockade of LAG3&PD1 may synergistically restore Tcell activation & enhance antitumor immunity. In a ph1/2a study, BMS986016 (antiLAG3)+nivolumab(antiPD1) showed promising antitumor activity in the melanoma prior IO cohort. Here, we describe updated efficacy & safety in a larger mel prior IO cohort in all-comer & biomarker-enriched populations.
Methods: Pts in the melanoma prior IO cohort received BMS-986016 80mg + nivolumab 240mg Q2W. Primary objectives were safety & objective response rate (ORR), disease control rate (DCR) & duration of response (DOR) per RECISTv1.1. Biomarker & efficacy correlations were also evaluated.
Results: As of June 15, 2017, 68 pts were treated; 57% had prior antiCTLA4 & 46% had ≥3 lines of prior therapy. In 61 efficacy-evaluable pts, ORR was 11.5 %(1 complete, 6 partial[1unconfirmed]responses); DCR was 49%. Median DOR was not reached (min [0.1+], max [39.3+]). ORR was ≥3.5-fold higher in pts with LAG3 expression ≥1%vs<1%, regardless of PDL1 expression. Response relationships with biomarker status & disease characteristics will be presented. Treatment-related AEs occurred in 51 %(gr3/4,10%; discontinuation[DC], 3.8%) of pts across all expansion cohorts (N=262) & in 41%(gr3/4, 4.4%; DC,1.5%) of pts in the mel prior IO cohort(n=68).
Conclusions: This is the largest report of outcomes in pts treated with anti-LAG3+antiPD-1. BMS-986016+nivolumab is well tolerated with a safety profile similar to nivolumab monotherapy & provides encouraging efficacy in a heavily pretreated, antiPD1/PDL1 progressed melanoma population. Enhanced responses correlated with LAG-3 expression, irrespective of PDL1 expression.
 
· · ·

Related Products

Thumbnail for Hrd1 protects regulatory T cells from ER stress-induced instability and dysfunction
Hrd1 protects regulatory T cells from ER stress-induced instability and dysfunction
HRD1 PROTECTS REGULATORY T CELLS FROM ER STRESS-INDUCED INSTABILITY AND DYSFUNCTION
Thumbnail for Attenuated Listeria monocytogenes as a promising vaccine candidate in the settings of hepatobiliary cancer
Attenuated Listeria monocytogenes as a promising vaccine candidate in the settings of hepatobiliary cancer
ATTENUATED _LISTERIA MONOCYTOGENES_ AS A PROMISING VACCINE CANDIDATE IN THE SETTINGS OF HEPATOBILIARY CANCER
Thumbnail for Therapy-induced necroptosis renders autochthonous mammary tumors susceptible to checkpoint blockade immunotherapy
Therapy-induced necroptosis renders autochthonous mammary tumors susceptible to checkpoint blockade immunotherapy
THERAPY-INDUCED NECROPTOSIS RENDERS AUTOCHTHONOUS MAMMARY TUMORS SUSCEPTIBLE TO CHECKPOINT BLOCKADE IMMUNOTHERAPY
Thumbnail for TLR Stimulation of Antigen-Presenting Cells Leads to IL-12 Expression that Decreases PD-1 Expression on Activated CD8+ T-Cells
TLR Stimulation of Antigen-Presenting Cells Leads to IL-12 Expression that Decreases PD-1 Expression on Activated CD8+ T-Cells
TLR STIMULATION OF ANTIGEN-PRESENTING CELLS LEADS TO IL-12 EXPRESSION THAT DECREASES
Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.